Hazra R, Chattopadhyay S, Mallick A, Gayen S, Roy S
Med Oncol. 2024; 41(7):175.
PMID: 38874788
DOI: 10.1007/s12032-024-02416-3.
Tominaga K, Toda E, Takeuchi K, Takakuma S, Sakamoto E, Kuno H
Pathol Int. 2024; 74(6):317-326.
PMID: 38634742
PMC: 11551812.
DOI: 10.1111/pin.13428.
Hayashi T, Lim K, Kovacs A, Mann D
JACC Basic Transl Sci. 2024; 8(12):1503-1517.
PMID: 38205352
PMC: 10774592.
DOI: 10.1016/j.jacbts.2023.07.012.
Xue W, Yuan X, Ji Z, Li H, Yao Y
Front Nutr. 2023; 10:1270920.
PMID: 37927510
PMC: 10620529.
DOI: 10.3389/fnut.2023.1270920.
Huang W, Su D, Liao X, Yang T, Lu Y, Zhang Z
Sci Rep. 2023; 13(1):789.
PMID: 36646765
PMC: 9842650.
DOI: 10.1038/s41598-023-27826-7.
CAR T-Cell Therapy for Patients with Multiple Myeloma: Current Evidence and Challenges.
Rendo M, Joseph J, Phan L, DeStefano C
Blood Lymphat Cancer. 2022; 12:119-136.
PMID: 36060553
PMC: 9439649.
DOI: 10.2147/BLCTT.S327016.
Advances and challenges of CAR T therapy and suitability of animal models (Review).
Ramos-Cardona X, Luo W, Mohammed S
Mol Clin Oncol. 2022; 17(3):134.
PMID: 35949897
PMC: 9353808.
DOI: 10.3892/mco.2022.2567.
Development of Cancer Immunotherapies.
DeLucia D, Lee J
Cancer Treat Res. 2022; 183:1-48.
PMID: 35551655
DOI: 10.1007/978-3-030-96376-7_1.
Lessons From the Success and Failure of Targeted Drugs for Rheumatoid Arthritis: Perspectives for Effective Basic and Translational Research.
Kim M, Choe Y, Lee S
Immune Netw. 2022; 22(1):e8.
PMID: 35291656
PMC: 8901706.
DOI: 10.4110/in.2022.22.e8.
Prognostic implication and immunotherapy response prediction of a costimulatory molecule signature in kidney renal clear cell carcinoma.
Lin G, Yang Y, Feng Q, Zhan F, Sun C, Niu Y
Immunogenetics. 2022; 74(3):285-301.
PMID: 35119508
DOI: 10.1007/s00251-021-01246-1.
Immune Checkpoint Inhibitor-Associated Colitis: From Mechanism to Management.
Tang L, Wang J, Lin N, Zhou Y, He W, Liu J
Front Immunol. 2022; 12:800879.
PMID: 34992611
PMC: 8724248.
DOI: 10.3389/fimmu.2021.800879.
Pulmonary Toxicities of Immunotherapy.
Altan M, Zhong L, Shannon V, Sheshadri A
Adv Exp Med Biol. 2022; 1342:357-375.
PMID: 34972974
DOI: 10.1007/978-3-030-79308-1_14.
Cyclosporine Broadens the Therapeutic Potential of Lenalidomide in Myeloid Malignancies.
Dou A, Fang J
J Cell Immunol. 2020; 2(5):237-244.
PMID: 32984863
PMC: 7518522.
DOI: 10.33696/immunology.2.049.
Structural Insights into N-terminal IgV Domain of BTNL2, a T Cell Inhibitory Molecule, Suggests a Non-canonical Binding Interface for Its Putative Receptors.
Basak A, Maiti S, Hansda A, Mahata D, Duraivelan K, Kundapura S
J Mol Biol. 2020; 432(22):5938-5950.
PMID: 32976909
PMC: 7642044.
DOI: 10.1016/j.jmb.2020.09.013.
Mechanisms and microbial influences on CTLA-4 and PD-1-based immunotherapy in the treatment of cancer: a narrative review.
Miller P, Carson T
Gut Pathog. 2020; 12:43.
PMID: 32944086
PMC: 7488430.
DOI: 10.1186/s13099-020-00381-6.
Deregulation of Adaptive T Cell Immunity in Multiple Myeloma: Insights Into Mechanisms and Therapeutic Opportunities.
Leblay N, Maity R, Hasan F, Neri P
Front Oncol. 2020; 10:636.
PMID: 32432039
PMC: 7214816.
DOI: 10.3389/fonc.2020.00636.
Immune-Related Adverse Events: Pneumonitis.
Zhong L, Altan M, Shannon V, Sheshadri A
Adv Exp Med Biol. 2020; 1244:255-269.
PMID: 32301020
PMC: 7161534.
DOI: 10.1007/978-3-030-41008-7_13.
Pulmonary Administration: Strengthening the Value of Therapeutic Proximity.
Videira M, Llop J, Sousa C, Kreutzer B, Cossio U, Forbes B
Front Med (Lausanne). 2020; 7:50.
PMID: 32181253
PMC: 7058098.
DOI: 10.3389/fmed.2020.00050.
Microglial Cells: The Main HIV-1 Reservoir in the Brain.
Wallet C, De Rovere M, Assche J, Daouad F, De Wit S, Gautier V
Front Cell Infect Microbiol. 2019; 9:362.
PMID: 31709195
PMC: 6821723.
DOI: 10.3389/fcimb.2019.00362.
Co-stimulatory and co-inhibitory pathways in cancer immunotherapy.
ONeill R, Cao X
Adv Cancer Res. 2019; 143:145-194.
PMID: 31202358
PMC: 7336166.
DOI: 10.1016/bs.acr.2019.03.003.
